Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial
Latest Information Update: 07 Feb 2023
At a glance
- Drugs COVID-2019 vaccine-Shenzhen Kangtai Biological Products (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- Sponsors Beijing Minhai Biotechnology
- 15 Jun 2021 New source identified and integrated ( Chinese Clinical Trial Register ChiCTR2000038804)
- 28 Apr 2021 Results from ChiCTR2000038804 and ChiCTR2000039462; assessing preliminary immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, published in the Chinese Medical Journal
- 19 Feb 2021 New trial record